RESUMEN
GPI-linked membrane folate receptors (MFRs) have been implicated in the receptor-mediated uptake of reduced folate cofactors and folate-based chemotherapeutic drugs. We have studied the biosynthetic transport to and internalization of MFR isoform alpha in KB-cells. MFR-alpha was synthesized as a 32-kD protein and converted in a maturely glycosylated 36-38-kD protein 1 h after synthesis. 32-kD MFR-alpha was completely soluble in Triton X-100 at 0 degree C. In contrast, only 33% of the 36-38-kD species could be solubilized at these conditions whereas complete solubilization was obtained in Triton X-100 at 37 degrees C or in the presence of saponin at 0 degree C. Similar solubilization characteristics were found when MFR-alpha at the plasma membrane was labeled with a crosslinkable 125I-labeled photoaffinity-analog of folic acid as a ligand. Triton X-100-insoluble membrane domains containing MFR-alpha could be separated from soluble MFR-alpha on sucrose flotation gradients. Only Triton X-100 soluble MFR-alpha was internalized from the plasma membrane. The reduced-folate-carrier, an integral membrane protein capable of translocating (anti-)folates across membranes, was completely excluded from the Triton X-100-resistant membrane domains. Internalized MFR-alpha recycled slowly to the cell surface during which it remained soluble in Triton X-100 at 0 degree C. Using immunoelectron microscopy, we found MFR-alpha along the entire endocytic pathway: in clathrin-coated buds and vesicles, and in small and large endosomal vacuoles. In conclusion, our data indicate that a large fraction, if not all, of internalizing MFR-alpha bypasses caveolae.
Asunto(s)
Proteínas Portadoras/metabolismo , Endocitosis/fisiología , Glicosilfosfatidilinositoles/metabolismo , Receptores de Superficie Celular/metabolismo , Transporte Biológico , Proteínas Portadoras/aislamiento & purificación , Fraccionamiento Celular , Membrana Celular/química , Membrana Celular/metabolismo , Centrifugación por Gradiente de Densidad , Receptores de Folato Anclados a GPI , Ácido Fólico/análogos & derivados , Antagonistas del Ácido Fólico/metabolismo , Glicosilación , Aparato de Golgi/efectos de los fármacos , Aparato de Golgi/metabolismo , Humanos , Ligandos , Microscopía Inmunoelectrónica , Octoxinol/farmacología , Oxidación-Reducción , Procesamiento Proteico-Postraduccional , Solubilidad , Células Tumorales CultivadasRESUMEN
The clonal cytotoxic effects and mechanism of action of a new series of 2-amino-4-hydroxyquinazoline folate analogues (5,8-dideazafolates) have been assessed using the human colon tumor cell line HCT-8. Of these compounds only 5-methyl-5,8-dideazafolate was potentially more effective than a compound previously identified, 5,8-dideazaisofolate (H-338, NSC 289517). HCT-8 sublines resistant to methotrexate, 5-fluorodeoxyuridine, and H-338 were either minimally or not cross-resistant to the other agents. The cytotoxicity of H-338 was strongly dependent on the time of exposure; at exposure times shorter than 8 h it was essentially nontoxic. Thymidine alone, as well as leucovorin or folic acid, protected against the cytotoxic effects of H-338. This is consistent with thymidylate synthase (TS) as its only locus of action. Studies with dihydrofolate reductase and TS isolated from HCT-8 cells indicated that these quinazolines were weaker inhibitors of dihydrofolate reductase than was methotrexate, but they were not particularly potent TS inhibitors. However, synthetic poly-gamma-glutamate derivatives of quinazolines showed dramatically increased TS, but not dihydrofolate reductase, inhibition. TS inhibition increased as the polyglutamate chain length increased. Using isolated HCT-8 folylpolyglutamate synthetase, all the parent quinazolines containing L-glutamate were found to be substrates. With H-338, the results indicated that tetraglutamate or longer derivatives could be synthesized intracellularly. These results are consistent with our hypothesis that cytotoxicity by such quinazolines necessarily involves "lethal synthesis" from a prodrug; i.e., the nontoxic parent drug must be converted to polyglutamates before TS inhibition and subsequent cytotoxicity can occur.
Asunto(s)
Antagonistas del Ácido Fólico/farmacología , Quinazolinas/farmacología , Supervivencia Celular/efectos de los fármacos , Neoplasias del Colon , Resistencia a Medicamentos , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Relación Estructura-Actividad , Células Tumorales Cultivadas/efectos de los fármacosRESUMEN
The substrate specificity of pig liver folylpolyglutamate synthetase (tetrahydrofolate:L-glutamate gamma-ligase (ADP-forming), EC 6.3.2.17) for classical 5,8-dideaza analogues of folic acid, isofolic acid aminopterin and isoaminopterin has been investigated. 5,8-Dideazafolate and 5,8-dideazaaminopterin are very effective substrates with activities approaching those of the best reduced folate substrates. The analogous isofolate analogues are less effective substrates, but still better than folic acid. The 5-chloro substituent is the only modification that consistently increases the on rate, with 5-chloro-5,8-dideazaaminopterin being the most effective substrate found, thus far, for the enzyme. Methylation at positions 9 or 10 generally decreases binding, while 5-methylation increases the binding of 4-oxoquinazolines, but decreases the binding of their 4-amino counterparts. The presence of a formyl group at N9 or N10 has the opposite effect, decreasing the binding of 4-oxo analogues while increasing the rate for 4-amino derivatives. Increases in on rate with methyl, formyl or 4-amino substitutions are only significant when the parent compound is a poor substrate, suggesting that these groups do not interact directly with the enzyme but cause conformational changes in the structure of the substrate that influence binding to the enzyme.
Asunto(s)
Aminopterina/análogos & derivados , Aminopterina/metabolismo , Ácido Fólico/análogos & derivados , Péptido Sintasas/metabolismo , Adenosina Trifosfato/metabolismo , Animales , Ácido Fólico/metabolismo , Glutamatos/metabolismo , Ácido Glutámico , Cinética , Estructura Molecular , Relación Estructura-Actividad , Especificidad por Sustrato , PorcinosRESUMEN
Formation of a quinoid-like structure within the glycyl-pyridoxal phosphate moiety of serine transhydroxymethylase (5,10-methylenetetrahydrofolate: glycine hydroxymethyltransferase, EC 2.1.2.1) is dependent upon the dissociation of the 2-S hydrogen of glycine which in turn requires the presence of tetrahydrofolate or analogs thereof. Equilibrium binding studies with the series folate, dihydrofolate, and tetrahydrofolate showed that reduction of the pteridine ring enhances both quinoid formation and binding. A 5,8-deazafolate series showed that modifications in the 4 position, 10 position and the glutamyl position yield interrelated alterations of quinoid formation which could not be correlated with binding.
Asunto(s)
Ácido Fólico/análogos & derivados , Glicina Hidroximetiltransferasa , Transferasas , Sitios de Unión , Glicina Hidroximetiltransferasa/metabolismo , Unión Proteica , Relación Estructura-Actividad , Transferasas/metabolismoRESUMEN
Dihydrofolate reductase (DHFR) inhibitors, which differ from the classical folate antagonists in physicochemical and pharmacologic parameters such as lipid solubility and mechanisms of cellular transport, were screened for DHFR inhibitory activity and biologic activity in newborn rat skin. The most effective drugs from this screen were tested for their effects on de novo DNA synthesis in psoriatic epidermis in vitro. Of the 24 compounds studied, methotrexate (MTX) was the most potent inhibitor of rat skin DHFR (I50=8.6 X 10(-9) M). Methotrexate-dimethylester, methasquin-diethylester, DDEP (2,4-diamino-5-(3',4'-dichlorophenyl)-6-ethylprimidine), and Baker's triazine antifolate (NSC 139105), while less effective than MTX as DHFR inhibitors, were more effective than MTX as inhibitors of de novo DNA synthesis in rat skin in vitro. Baker's antifolate was the only compound tested which was considerably more effective than MTX as an inhibitor of de novo DNA synthesis in psoriatic epidermis in vitro.
Asunto(s)
Antagonistas del Ácido Fólico/metabolismo , Piel/metabolismo , Animales , Animales Recién Nacidos , Clorobencenos/farmacología , ADN/biosíntesis , Depresión Química , Antagonistas del Ácido Fólico/farmacología , Metotrexato/farmacología , Psoriasis/metabolismo , Pirimetamina/farmacología , Pirimidinas/farmacología , Quinazolinas/farmacología , Ratas , Tetrahidrofolato Deshidrogenasa/metabolismo , Triazinas/farmacología , Trimetoprim/farmacologíaRESUMEN
The quinazoline couterpart of folic acid (5,8-deazafolic acid) as well as its 10-methyl analogue has been shown to be an effective inhibitor of thymidylate synthetase from several different sources. This paper describes the synthesis of modifications in which the nitrogen atom at position 10 is replaced by sulfur, oxygen, or methylene affording 10-thia-5,8-deazafolic acid, 10-oxa-5,8-deazafolic acid, and 5,8,10-deazafolic acid, respectively. In preliminary testing, each of the target compounds displayed marginal activity against L1210 leukemia in mice.
Asunto(s)
Antineoplásicos/síntesis química , Ácido Fólico/análogos & derivados , Quinazolinas/síntesis química , Animales , Antineoplásicos/uso terapéutico , Ácido Fólico/síntesis química , Ácido Fólico/uso terapéutico , Leucemia L1210/tratamiento farmacológico , Ratones , Quinazolinas/uso terapéuticoRESUMEN
Four quinazoline analogs of isofolic acid were synthesized including 5-methyl-5,8-deazaisofolic acid (8a), 5,8-deazaisofolic acid (8c), as well as their 4-NH2 counterparts 8b and 8d. None of these showed significant activity against L1210 leukemia in mice at dose levels where amethopterin provided significant prolongation in survival.
Asunto(s)
Ácido Fólico/análogos & derivados , Quinazolinas/síntesis química , Animales , Ácido Fólico/síntesis química , Ácido Fólico/uso terapéutico , Antagonistas del Ácido Fólico , Técnicas In Vitro , Leucemia L1210/tratamiento farmacológico , Hígado/enzimología , Ratones , Quinazolinas/farmacología , Quinazolinas/uso terapéutico , Ratas , Relación Estructura-ActividadRESUMEN
A series of 2,4-diaminoquinazolines bearing an aryl function attached to the 6 position through an acetamido or related linkage was synthesized. Each compound was evaluated as an inhibitor of rat liver dihydrofolate reductase as well as for suppressive antimalarial effects against Plasmodium berghei in mice. Significant in vivo activity was found to reside primarily with 5-chloro-6-arylacetamido derivatives. Most of these compounds were also tested for prophylactic activity against sporozoite-induced Plasmodium gallinaceum in chicks. Thirteen compounds, each of which possesses a 5-Cl or 5-CH3 group, displayed curative activity in this test system. Since several of these showed markedly greater potency against the avian infection, selective inhibitory action upon preerythrocytic forms of the malaria parasite is thus implied.
Asunto(s)
Antagonistas del Ácido Fólico/síntesis química , Quinazolinas/síntesis química , Animales , Antimaláricos/síntesis química , Antimaláricos/uso terapéutico , Pollos , Diaminas/síntesis química , Diaminas/farmacología , Diaminas/uso terapéutico , Antagonistas del Ácido Fólico/farmacología , Antagonistas del Ácido Fólico/uso terapéutico , Hígado/enzimología , Malaria/tratamiento farmacológico , Ratones , Plasmodium berghei , Quinazolinas/farmacología , Quinazolinas/uso terapéutico , RatasRESUMEN
Several classical quinazoline analogues of folic acid bearing chloro or methyl substituents at position 5 were evaluated as inhibitors of the growth of four human gastrointestinal adenocarcinoma cell lines in vitro. The preparation of two of these, 5-chloro-5,8-dideazaisofolic acid, 1e, and 5-chloro-5,8-dideazaisoaminopterin, 2a, is reported for the first time. In addition, a new synthetic route to 5-chloro-5,8-dideazaaminopterin, 2b, is described. For compounds having a 2,4-diamino configuration, the presence of chlorine at position 5 afforded superior growth inhibitory potency. However, compound 1e was substantially less effective than its 5-methyl counterpart.
Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Aminopterina/análogos & derivados , Neoplasias del Colon/tratamiento farmacológico , Quinazolinas/uso terapéutico , Aminopterina/síntesis química , Aminopterina/uso terapéutico , Línea Celular , Fenómenos Químicos , Química , Humanos , Quinazolinas/síntesis química , Relación Estructura-ActividadRESUMEN
Five new N alpha-(5,8-dideazapteroyl)-L-ornithines have been prepared using multistep synthetic sequences. These include N alpha-[5-(trifluoromethyl)-5,8-dideazapteroyl]-L-ornithine, 3, as well as N alpha-[5-(trifluoromethyl)-5,8-dideazaisopteroyl]-L-ornithine, 4, and its 5-fluoro and 5-chloro analogues. Both of the compounds containing a 5-(trifluoromethyl) group (3 and 4) were found to be excellent inhibitors of homogeneous hog liver folylpolyglutamate synthetase, having Ki values in the same range as N alpha-(5-chloro-5,8-dideazapteroyl)-L-ornithine, 2, (approximately 10 nM). However, the bridge-reversed isomer of 2 was 60-fold less inhibitory than 2.
Asunto(s)
Ácido Fólico/análogos & derivados , Hígado/enzimología , Ornitina/análogos & derivados , Péptido Sintasas/antagonistas & inhibidores , Animales , Ácido Fólico/síntesis química , Ácido Fólico/farmacología , Cinética , Ornitina/síntesis química , Ornitina/farmacología , Relación Estructura-Actividad , PorcinosRESUMEN
A new synthetic route to 5,8-dideazaisofolic acid (IAHQ) is described which precludes the possibility of contamination due to its 4-amino counterpart 5,8-dideazaisoaminopterin. Substitution of D-glutamic acid in this synthetic scheme gave D-IAHQ. The 9-formyl, 9-methyl, 5-methyl, and 5,9-dimethyl modifications of IAHQ were also prepared. These compounds, together with several structurally related or isomeric analogues, were studied for inhibitory effects upon the growth of four human gastrointestinal adenocarcinoma cell lines in vitro. In general, the compounds having a normal folate configuration at positions 9 and 10 are more active than their reversed bridge isomers. The lack of antitumor activity of D-IAHQ provides indirect evidence concerning the mechanism of action of IAHQ.
Asunto(s)
Antineoplásicos/uso terapéutico , Quinazolinas/síntesis química , Adenocarcinoma/tratamiento farmacológico , Línea Celular , Fenómenos Químicos , Química , Antagonistas del Ácido Fólico , Neoplasias Gastrointestinales/tratamiento farmacológico , Humanos , Metotrexato/uso terapéutico , Quinazolinas/uso terapéutico , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
Six new 5,8-dideaza analogues of folic acid and aminopterin containing a terminal L-ornithine residue were prepared by using multistep synthetic sequences. Each was evaluated as an inhibitor of hog liver folylpolyglutamate synthetase and human dihydrofolate reductase. Structural modifications at positions 2, 4, 5, and 10 were included to help define structure-activity relationships for compounds of this type. The compound N alpha-(4-amino-4-deoxy-5-chloro-5,8-dideazapteroyl)-L-ornithine (3f) was identified as the most potent inhibitor of mammalian folylpolyglutamate synthetase reported thus far (Ki congruent to 2 nM). Its 4-oxy counterpart, N alpha-(5-chloro-5,8-dideazapteroyl)-L-ornithine, was only 5-fold less inhibitory than 3f toward folylpolyglutamate synthetase but was found to be a much weaker inhibitor of dihydrofolate reductase than 3f.
Asunto(s)
Aminopterina/farmacología , Antagonistas del Ácido Fólico , Ácido Fólico/farmacología , Ornitina , Péptido Sintasas/antagonistas & inhibidores , Aminopterina/antagonistas & inhibidores , Animales , Fenómenos Químicos , Química , Ácido Fólico/análogos & derivados , Humanos , Cinética , Hígado/enzimología , Oxidación-Reducción , Especificidad por Sustrato , PorcinosRESUMEN
Three new 5,8-dideaza analogues of folic acid devoid of an amino group at position 2 have been prepared by using synthetic routes patterned after earlier methodologies. They were 2-desamino-5,8-dideazaisofolic acid, 2b, 2-desamino-10-thia-5,8-dideazafolic acid, 2c, and 2-desamino-10-oxa-5,8-dideazafolic acid, 2d. These compounds were found to be 4-6-fold more cytoxic toward L1210 leukemia cells than their 2-NH2 counterparts and to be poor inhibitors of mammalian thymidylate synthase. However, they were only 1.5-3-fold less inhibitory toward dihydrofolate reductase than the analogous compounds containing a 2-NH2 group. The known thymidylate synthase inhibitors 2-desamino-10-propargyl-5,8-dideazafolic acid and 10-propargyl-5,8-dideazafolic acid were included in this study for purposes of comparison.
Asunto(s)
Ácido Fólico/análogos & derivados , Quinazolinas/farmacología , Animales , Fenómenos Químicos , Química , Ácido Fólico/farmacología , Ácido Fólico/uso terapéutico , Antagonistas del Ácido Fólico , Humanos , Leucemia L1210/tratamiento farmacológico , Leucemia L1210/enzimología , Metotrexato/uso terapéutico , Quinazolinas/síntesis química , Quinazolinas/uso terapéutico , Relación Estructura-Actividad , Timidilato Sintasa/antagonistas & inhibidoresRESUMEN
Recent demonstrations that deazafolate analogues may act as potent inhibitors of thymidylate synthase (TS) provided a firm rationale for the synthesis of N10-propargyl derivatives of 8-deazafolate and 8-deazaaminopterin (4). A complete assignment of the 1H NMR spectra of these compounds was made possible through application of 2D (COSY) techniques at 200 MHz. Data describing the inhibition of TS derived from human leukemia (K562) cells are presented. IC50 values of 2.25 and 1.26 microM were determined for 8-deaza-10-propargylfolate (3) and 8-deaza-10-propargylaminopterin, respectively. Comparison of the data for various folate analogues reveals a striking dependence of TS inhibitory potency upon the number of nitrogens in the folate pyrazine ring.
Asunto(s)
Aminopterina/análogos & derivados , Antagonistas del Ácido Fólico/farmacología , Ácido Fólico/análogos & derivados , Timidilato Sintasa/antagonistas & inhibidores , Aminopterina/farmacología , Ácido Fólico/farmacología , Antagonistas del Ácido Fólico/síntesis química , Humanos , Leucemia Mieloide Aguda/enzimología , Espectroscopía de Resonancia Magnética , Proteínas de Neoplasias/antagonistas & inhibidores , Relación Estructura-ActividadRESUMEN
A series of classical quinazoline analogues of folic and isofolic acids was evaluated for inhibitory activity against the dihydrofolate reductases from rat liver and from Streptococcus faecium. Included in this group were the known active antitumor agents methasquin and chlorasquin as well as methotrexate. Two new compounds, N10-formyl-5,8-deazaaminopterin and N10-formyl-5,8-deazafolic acid, were synthesized specifically for this study. The latter displayed modest activity against L1210 leukemia in mice.
Asunto(s)
Antagonistas del Ácido Fólico , Ácido Fólico/análogos & derivados , Quinazolinas/farmacología , Animales , Antineoplásicos/síntesis química , Antineoplásicos/uso terapéutico , Fenómenos Químicos , Química , Ácido Fólico/síntesis química , Ácido Fólico/farmacología , Ácido Fólico/uso terapéutico , Técnicas In Vitro , Leucemia L1210/tratamiento farmacológico , Hígado/efectos de los fármacos , Hígado/enzimología , Ratones , Quinazolinas/síntesis química , Quinazolinas/uso terapéutico , Ratas , Streptococcus/efectos de los fármacos , Streptococcus/enzimología , Relación Estructura-ActividadRESUMEN
A series of 19 quinazoline analogs of pteroic and isopteroic acid was prepared with particular emphasis being placed upon carboxylic acid esters. Each compound was evaluated as an inhibitor of the dihydrofolate reductases from rat liver as well as from Streptococcus faecium. Several of the more potent inhibitors were found to be inactive against L1210 leukemia in mice at low dose levels and were lethal to mice at 100 mg/kg. Six compounds were also evaluated for antimalarial activity against Plasmodium berghei in mice. Three of these were found to be curative at higher levels, while the remaining compounds were found to be toxic.
Asunto(s)
Antagonistas del Ácido Fólico , Pterinas/síntesis química , Quinazolinas/síntesis química , Animales , Enterococcus faecalis/enzimología , Técnicas In Vitro , Leucemia L1210/tratamiento farmacológico , Hígado/enzimología , Malaria/tratamiento farmacológico , Ratones , Plasmodium berghei , Pterinas/farmacología , Pterinas/uso terapéutico , Quinazolinas/farmacología , Quinazolinas/uso terapéutico , RatasRESUMEN
Prompted by recent disclosures concerning the potent antitumor activities of 5-deaza-5,6,7,8-tetrahydrofolic acid and 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF), we have prepared 5-deazaisofolic acid (3a) and 5-deaza-5,6,7,8-tetrahydroisofolic acid (4a). Reductive condensation of 2,6-diamino-3,4-dihydro-4- oxopyrido[2,3-d]pyrimidine with di-tert-butyl N-(4-formylbenzoyl)-L-glutamate and subsequent deprotection with trifluoroacetic acid yielded 5-deazaisofolic acid in good yield. Catalytic hydrogenation of this analogue then gave 4a. The 9-CH3 and 9-CHO modifications of 3a and the 9-CH3 derivative of 4a were also synthesized. Each of the new analogues was evaluated with a variety of folate-requiring enzymes as well as MCF-7 cells in culture. Compound 4a had an IC50 of ca. 1 microM against MCF-7 cells and was nearly 100-fold less potent than DDATHF in this regard. The three oxidized isofolate analogues were all poor inhibitors of tumor cell growth.
Asunto(s)
Antineoplásicos/síntesis química , Ácido Fólico/análogos & derivados , Tetrahidrofolatos/síntesis química , Animales , Antineoplásicos/uso terapéutico , Ácido Fólico/síntesis química , Ácido Fólico/uso terapéutico , Antagonistas del Ácido Fólico , Humanos , Relación Estructura-Actividad , Porcinos , Tetrahidrofolatos/uso terapéutico , Timidilato Sintasa/antagonistas & inhibidoresRESUMEN
A novel folic acid analogue, N alpha-(5-deaza-5,6,7,8-tetrahydropteroyl)-L-ornithine, 3, was prepared via a multistep synthetic sequence. The key steps involved the conversion of 5-deazapteroic acid to its N10-formyl derivative followed by catalytic hydrogenation of the pyridine ring and subsequent heating in dilute sodium hydroxide to afford the new 5-deaza-5,6,7,8-tetrahydropteroic acid. After trifluoroacetylation, this compound was coupled to N delta-(tert-butyl-oxycarbonyl)-L-ornithine using conventional peptide bond forming conditions. Deprotection first in base and then in acid gave the title compound. Compound 3 was an effective inhibitor of hog liver folylpolyglutamate synthetase (Kis, estimated = 64 nM), and was shown to retard the formation of polyglutamates of a structurally related folic acid analogue in HCT-8 cells in vitro.
Asunto(s)
Ácido Fólico/análogos & derivados , Péptido Sintasas/antagonistas & inhibidores , Adenocarcinoma/metabolismo , Animales , Neoplasias de la Mama/metabolismo , Supervivencia Celular/efectos de los fármacos , Ácido Fólico/síntesis química , Ácido Fólico/metabolismo , Ácido Fólico/farmacología , Antagonistas del Ácido Fólico , Humanos , Hígado/enzimología , Ácido Poliglutámico/metabolismo , Porcinos , Células Tumorales CultivadasRESUMEN
A series of six 2,4-diaminoquinazoline analogues of folic acid which bear close structural resemblance to methotrexate, 1a, were synthesized by unequivocal routes. Three of these have not been described previously, while complete structural characterization of the remaining compounds is presented for the first time. Each of the compounds was a potent inhibitor of dihydrofolate reductase (DHFR) from rat liver or L1210 leukemia cells having I50 values in a range similar to that of 1a. However, a wide divergence in inhibitory activity toward the growth of human gastrointestinal adenocarcinoma or L1210 leukemia cells in vitro was observed. Compounds having a normal folate configuration at positions 9 and 10 were more inhibitory than their isomeric reversed-bridge counterparts. The N-formyl modifications were the least active of the compounds studied. Unsubstituted or N-methyl modifications competed effectively with tritiated 1a for uptake into L1210 leukemia cells, while N-formyl modifications did not. Against an L1210 cell line resistant to 1a by virtue of altered transport and overproduction of DHFR, partial but not complete cross-resistance was observed for certain analogues. Of the three compounds selected for in vivo evaluation against L1210 leukemia in mice, two had a similar level of antitumor activity to that of 1a. The compound 5,8-dideazamethopterin, 2b, however, was slightly more active than 1a but at substantially reduced dose levels.
Asunto(s)
Antineoplásicos/síntesis química , Metotrexato/análogos & derivados , Adenocarcinoma/tratamiento farmacológico , Animales , Línea Celular , Antagonistas del Ácido Fólico , Neoplasias Gastrointestinales/tratamiento farmacológico , Humanos , Leucemia L1210/tratamiento farmacológico , Leucemia L1210/enzimología , Hígado/enzimología , Metotrexato/síntesis química , Metotrexato/uso terapéutico , RatonesRESUMEN
A series of 5,8-dideaza analogues of folic acid, isofolic acid, aminopterin, and isoaminopterin were evaluated for inhibition of thymidylate synthase, TS, from mouse L1210 leukemia cells with 10-propargyl-5,8-dideazafolic acid, CB3717, 4a, as the reference inhibitor. These compounds were also tested as inhibitors of human dihydrofolate reductase, DHFR, obtained from WIL2 cells. None of the analogues studied were as potent as 4a toward TS; however, 9-methyl-5,8-dideazaisoaminopterin, 6d, was only 2.5-fold less effective. Compound 4a was prepared by direct alkylation of the di-tert-butyl ester of 5,8-dideazafolic acid followed by hydrolysis of the resulting diethyl ester, which resulted from concomitant transesterification. It was found to be identical with a sample of 4a prepared by earlier methodology by using a variety of spectroscopic techniques. Its isomer, 9-propargyl-5,8-dideazaisofolic acid, 4b, which was synthesized by an analogous approach, was found to be dramatically less inhibitory toward TS than 4a. Each of the 2,4-diamino derivatives, including those possessing an allyl or propargyl group at N9, was an excellent inhibitor of DHFR, having a level of potency similar to that of methotrexate, MTX. However, many of these 5,8-dideazaaminopterin analogues were far more inhibitory toward TS than MTX.